D Malaspina1, E Lotan2, H Rusinek2, S A Perez2, J Walsh-Messinger3,4, T M Kranz5, O Gonen2. 1. From the Departments of Psychiatry, Neuroscience, Genetics, and Genomics (D.M.), Icahn School of Medicine at Mount Sinai, New York, New York Dolores.malaspina@mssm.edu. 2. Department of Radiology (E.L., H.R., S.A.P., O.G.), Center for Advanced Imaging Innovation and Research, New York University Grossman School of Medicine, New York, New York. 3. Department of Psychology (J.W.-M.), University of Dayton, Dayton, Ohio. 4. Department of Psychiatry (J.W.-M.), Wright State University Boonshoft School of Medicine, Dayton, Ohio. 5. Department of Psychiatry, Psychosomatics, and Psychotherapy (T.M.K.), Goethe University, Frankfurt, Germany.
Abstract
BACKGROUND AND PURPOSE: Previous hippocampal proton MR spectroscopic imaging distinguished patients with schizophrenia from controls by elevated Cr levels and significantly more variable NAA and Cho concentrations. This goal of this study was to ascertain whether this metabolic variability is associated with clinical features of the syndrome, possibly reflecting heterogeneous hippocampal pathologies and perhaps variability in its "positive" (psychotic) and "negative" (social and emotional deficits) symptoms. MATERIALS AND METHODS: In a sample of 15 patients with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, we examined the association of NAA and Cho levels with research diagnostic interviews and clinical symptom ratings of the patients. Metabolite concentrations were previously obtained with 3D proton MR spectroscopic imaging at 3T, a technique that facilitates complete coverage of this small, irregularly shaped, bilateral, temporal lobe structure. RESULTS: The patient cohort comprised 8 men and 7 women (mean age, 39.1 [SD, 10.8] years, with a mean disease duration of 17.2 [SD, 10.8] years. Despite the relatively modest cohort size, we found the following: 1) Elevated Cho levels predict the positive (psychotic, r = 0.590, P = .021) and manic (r = 0.686, P = .005) symptom severity; and 2) lower NAA levels trend toward negative symptoms (r = 0.484, P = .08). No clinical symptoms were associated with Cr level or hippocampal volume (all, P ≥ .055). CONCLUSIONS: These preliminary findings suggest that NAA and Cho variations reflect different pathophysiologic processes, consistent with microgliosis/astrogliosis and/or lower vitality (reduced NAA) and demyelination (elevated Cho). In particular, the active state-related symptoms, including psychosis and mania, were associated with demyelination. Consequently, their deviations from the means of healthy controls may be a marker that may benefit precision medicine in selection and monitoring of schizophrenia treatment.
BACKGROUND AND PURPOSE: Previous hippocampal proton MR spectroscopic imaging distinguished patients with schizophrenia from controls by elevated Cr levels and significantly more variable NAA and Cho concentrations. This goal of this study was to ascertain whether this metabolic variability is associated with clinical features of the syndrome, possibly reflecting heterogeneous hippocampal pathologies and perhaps variability in its "positive" (psychotic) and "negative" (social and emotional deficits) symptoms. MATERIALS AND METHODS: In a sample of 15 patients with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, we examined the association of NAA and Cho levels with research diagnostic interviews and clinical symptom ratings of the patients. Metabolite concentrations were previously obtained with 3D proton MR spectroscopic imaging at 3T, a technique that facilitates complete coverage of this small, irregularly shaped, bilateral, temporal lobe structure. RESULTS: The patient cohort comprised 8 men and 7 women (mean age, 39.1 [SD, 10.8] years, with a mean disease duration of 17.2 [SD, 10.8] years. Despite the relatively modest cohort size, we found the following: 1) Elevated Cho levels predict the positive (psychotic, r = 0.590, P = .021) and manic (r = 0.686, P = .005) symptom severity; and 2) lower NAA levels trend toward negative symptoms (r = 0.484, P = .08). No clinical symptoms were associated with Cr level or hippocampal volume (all, P ≥ .055). CONCLUSIONS: These preliminary findings suggest that NAA and Cho variations reflect different pathophysiologic processes, consistent with microgliosis/astrogliosis and/or lower vitality (reduced NAA) and demyelination (elevated Cho). In particular, the active state-related symptoms, including psychosis and mania, were associated with demyelination. Consequently, their deviations from the means of healthy controls may be a marker that may benefit precision medicine in selection and monitoring of schizophrenia treatment.
Authors: J Stedehouder; J J Couey; D Brizee; B Hosseini; J A Slotman; C M F Dirven; G Shpak; A B Houtsmuller; S A Kushner Journal: Cereb Cortex Date: 2017-10-01 Impact factor: 5.357
Authors: Marina Boccardi; Martina Bocchetta; Liana G Apostolova; Josephine Barnes; George Bartzokis; Gabriele Corbetta; Charles DeCarli; Leyla deToledo-Morrell; Michael Firbank; Rossana Ganzola; Lotte Gerritsen; Wouter Henneman; Ronald J Killiany; Nikolai Malykhin; Patrizio Pasqualetti; Jens C Pruessner; Alberto Redolfi; Nicolas Robitaille; Hilkka Soininen; Daniele Tolomeo; Lei Wang; Craig Watson; Henrike Wolf; Henri Duvernoy; Simon Duchesne; Clifford R Jack; Giovanni B Frisoni Journal: Alzheimers Dement Date: 2014-08-15 Impact factor: 21.566
Authors: Scott A Small; Scott A Schobel; Richard B Buxton; Menno P Witter; Carol A Barnes Journal: Nat Rev Neurosci Date: 2011-09-07 Impact factor: 34.870
Authors: Peter Joe; Jose C Clemente; Enrica Piras; David S Wallach; Jessica Robinson-Papp; Emeka Boka; Brooke Remsen; Mharisi Bonner; David Kimhy; Deborah Goetz; Kevin Hoffman; Jakleen Lee; Eugene Ruby; Sarah Fendrich; Oded Gonen; Dolores Malaspina Journal: Schizophr Res Date: 2021-10-06 Impact factor: 4.662